Severe Angioedema after Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor

Letters and Corrections15 February 1990Severe Angioedema after Long-Term Use of an Angiotensin-Converting Enzyme InhibitorHomer L. Chin, MD, Debra A. Buchan, MDHomer L. Chin, MD, Debra A. Buchan, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-4-312_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:Angiotensin-Converting enzyme (ACE) inhibitors have been in clinical use since 1980. They are effective antihypertensive agents with a good safety profile (1). Reported side effects include cough, azotemia, hypotension, hyperkalemia, and angioedema. Studies (2, 3) have reported the incidence of angioedema associated with the use of ACE inhibitors to be between 0.1% and 0.2%, but they did not emphasize the potential for severe life-threatening angioedema after long-term use. Another study (4) mentions a patient who was continued on the ACE inhibitor lisinopril even after a transient episode of angioedema. We report the case of a patient who...References1. Warner N and Rush J. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs. 1988;35(Suppl 5):89-97. CrossrefMedlineGoogle Scholar2. Inman W, Rawson N, Wilton L, Pearce G, and Speirs C. Post-marketing surveillance of enalapril. I. Results of prescription-event monitoring. BMJ 1988;297:826-9. CrossrefMedlineGoogle Scholar3. Slater E, Merrill D, and Guess H. Clinical profile of angioedema associated with angiotensin coverting-enzyme inhibition. JAMA. 1988;260:967-70. CrossrefMedlineGoogle Scholar4. Donohoe J, Kelly J, Laher M, and Doyle G. Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988;85:31-4. CrossrefMedlineGoogle Scholar5. Wood S, Mann R, and Rawlins M. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J [Clin Res]. 1987;294:91-2. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Homer L. Chin, MD; Debra A. Buchan, MDAffiliations: The Permanente Medical Group, Inc. San Jose, CA 95119 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInteraction Studies of ACE Inhibitors with Antidiabetic DrugsMedications and Oral Health: Points to Consider in Older PeopleAngiotensin-converting Enzyme Inhibitors-induced AngioedemaLife threatening angioedema in a patient on ACE inhibitor (ACEI) confined to the upper airwayFresh Frozen Plasma for Progressive and Refractory Angiotensin-Converting Enzyme Inhibitor-induced Angioedema3D QSAR kNN-MFA studies on 6-substituted benzimidazoles derivatives as Nonpeptide Angiotensin II Receptor Antagonists: A rational approach to antihypertensive agentsTetrazole‐Based Angiotensin II Type 1 (AT 1 ) Antagonists for the Treatment of Heart Failure and Congestive HypertensionWITHDRAWN: Predicting substituted 2-butylbenzimidazoles derivatives as angiotensin II receptor antagonists: 3D-QSAR and pharmacophore modelingDrug ReactionsAngiotensin-Converting Enzyme Inhibitors and AngioedemaToxicodermias inducidas por fármacosSynthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonistsAb Initio Study of Non-Peptidic AntihypertensivesNitroprusside, ACE Inhibitors, and Other Cardiovascular AgentsMedications' impact on oral healthDrug-Induced Respiratory Disease in Connective Tissue DiseasesThe Preferential Inhibitory Effect of Olmesartan, a New Angiotensin II Type 1 Antagonist, on Sympathetic Nerve Terminals in Isolated Canine Splenic ArteryAngiotensin-converting enzyme inhibitor therapy: adverse effects encountered by the otolaryngologistAngioedema After Interferon Therapy for Chronic Hepatitis CThe Inhibitory Effect of KT3-671, a Nonpeptide Angiotensin-Receptor Antagonist, on Rabbit and Rat Isolated Vascular Smooth Muscles: A Possible Involvement of KATP ChannelsAngioedema due to ACE inhibitors: increased risk in patients of African originAcute Angioedema Associated with Long-Term Benazepril TherapySerum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedemaSUBGLOTTIC STENOSIS: AN UNUSUAL PRESENTATION OF ACE INHIBITOR‐INDUCED ANGIOEDEMATongue angioedema after long-term use of ACE inhibitorsLate-Onset Life-Threatening Angioedema and Upper Airway Obstruction Caused by Angiotensin-Converting Enzyme Inhibitor: Report of a CaseAngiotensin-converting enzyme (ACE) inhibitors and angio-oedemaAngiotensin–converting enzyme (ACE) inhibitors and angio–oedemaLebensberdrohliche Zungenschwellung bei antihypertensiver Therapie mit ACE-HemmernPharmacological Profiles of a Novel Non-peptide Angiotensin II Type I Receptor Antagonist HR720 In Vitro and In VivoA Case Report of Angioedema During Long-term (66 Months) Angiotensin Converting Enzyme Inhibition Therapy With EnalaprilPharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonistIn vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonistAngio-oedema induced by enalaprilPharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonistIncreased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patientsDiscovery of nonpeptide potent conformationally restricted angiotensin II receptor antagonistsAtypical Presentation of Angioedema Associated with an Angiotensin-Converting Enzyme InhibitorAngioedema secondary to angiotensin-converting enzyme inhibitorsAngiotensin-Converting Enzyme Inhibitor Therapy for Congestive Heart Failure: Rationale, Results, and Current RecommendationsFrom Localized Angioedema to Generalized Capillary Leak Syndrome: Evidence for a Pivotal Role of C1-Inhibitor in Septic Shock-like SyndromesA medicinal chemistry case study: An account of an angiotensin II antagonist drug discovery programme4,5,6,7-Tetrahdryo-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiiotensin II receptor antagonistsQuinoline, 1,5-naphthyridine and pyridine derivatives as potent, nonpeptidic angiotensin II receptor antagonistsDrug discoveryAngiotensin-converting enzyme inhibitor-induced angioedema: Still unrecognizedFatal Angioedema Associated with LisinoprilPredisposition to and Late Onset of Upper Airway Obstruction following Angiotensin-Converting Enzyme Inhibitor TherapyCough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy A Review of the Literature and PathophysiologyZafar H. Israili, PhD, W. Dallas Hall, MDAngioedema associated with lisinoprilAngio-oedema in relation to treatment with angiotensin converting enzyme inhibitors.Angioedema after Substituting Lisinopril for CaptoprilSean McElligott, PharmD, Mark Perlroth, MD, Linda Raish, PharmDAnaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzerClinical characteristics of angiotensinconverting enzyme inhibitor-induced angioedemaDrug receptors and control of the cardiovascular system: Recent advancesDelayed Drug-Induced Periorbital Angioedema 15 February 1990Volume 112, Issue 4Page: 312-313KeywordsACE inhibitorsAngiotensin converting enzymeAngiotensin converting enzyme inhibitorHypotensionSafety ePublished: 1 December 2008 Issue Published: 15 February 1990 PDF downloadLoading ...